21 May 2013
Keywords: merck, co, singulair, oked, rhinitis, been, granted
Article | 06 January 2003
Merck & Co has been granted US approval to market its orally-activeleukotriene antagonist Singulair (montelukast sodium) for the relief of
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
6 January 2003
20 May 2013
© 2013 thepharmaletter.com